TY - JOUR
T1 - An evaluation of patient-reported outcomes in sickle cell disease within a conceptual model
AU - For the Sickle Cell Disease Implementation Consortium (SCDIC)
AU - Treadwell, Marsha J.
AU - Mushiana, Swapandeep
AU - Badawy, Sherif M.
AU - Preiss, Liliana
AU - King, Allison A.
AU - Kroner, Barbara
AU - Chen, Yumei
AU - Glassberg, Jeffrey
AU - Gordeuk, Victor
AU - Shah, Nirmish
AU - Snyder, Angela
AU - Wun, Theodore
N1 - Funding Information:
Drs. Treadwell, Mushiana, Badawy, Preiss, King, Kroner, Glassberg, Gordeuk, Snyder, Wun and Ms. Chen have none to declare. Dr. Shah receives research funding from Global Blood Therapeutics, is a consultant for Novartis, Emmaus Medical and Forma Therapeutics and a speaker for Global Blood Therapeutics and Novartis.
Funding Information:
The Sickle Cell Disease Implementation Consortium (SCDIC) has been supported by US Federal Government cooperative agreements HL133948, HL133964, HL133990, HL133996, HL133994, HL133997, HL134004, HL134007, and HL134042 from the National Heart Lung and Blood Institute and the National Institute on Minority Health and Health Disparities (Bethesda, MD).
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/9
Y1 - 2022/9
N2 - Purpose: To examine the relations between patient-reported outcomes (PROs) within a conceptual model for adults with sickle cell disease (SCD) ages 18 – 45 years enrolled in the multi-site Sickle Cell Disease Implementation Consortium (SCDIC) registry. We hypothesized that patient and SCD-related factors, particularly pain, and barriers to care would independently contribute to functioning as measured using PRO domains. Methods: Participants (N = 2054) completed a 48-item survey including socio-demographics and PRO measures, e.g., social functioning, pain impact, emotional distress, and cognitive functioning. Participants reported on lifetime SCD complications, pain episode frequency and severity, and barriers to healthcare. Results: Higher pain frequency was associated with higher odds of worse outcomes in all PRO domains, controlling for age, gender and site (OR range 1.02–1.10, 95% CI range [1.004–1.12]). Reported history of treatment for depression was associated with 5 of 7 PRO measures (OR range 1.58–3.28 95% CI range [1.18–4.32]). Fewer individual barriers to care and fewer SCD complications were associated with better outcomes in the emotion domain (OR range 0.46–0.64, 95% CI range [0.34–0.86]). Conclusions: Study results highlight the importance of the biopsychosocial model to enhance understanding of the needs of this complex population, and to design multi-dimensional approaches for providing more effective interventions to improve outcomes.
AB - Purpose: To examine the relations between patient-reported outcomes (PROs) within a conceptual model for adults with sickle cell disease (SCD) ages 18 – 45 years enrolled in the multi-site Sickle Cell Disease Implementation Consortium (SCDIC) registry. We hypothesized that patient and SCD-related factors, particularly pain, and barriers to care would independently contribute to functioning as measured using PRO domains. Methods: Participants (N = 2054) completed a 48-item survey including socio-demographics and PRO measures, e.g., social functioning, pain impact, emotional distress, and cognitive functioning. Participants reported on lifetime SCD complications, pain episode frequency and severity, and barriers to healthcare. Results: Higher pain frequency was associated with higher odds of worse outcomes in all PRO domains, controlling for age, gender and site (OR range 1.02–1.10, 95% CI range [1.004–1.12]). Reported history of treatment for depression was associated with 5 of 7 PRO measures (OR range 1.58–3.28 95% CI range [1.18–4.32]). Fewer individual barriers to care and fewer SCD complications were associated with better outcomes in the emotion domain (OR range 0.46–0.64, 95% CI range [0.34–0.86]). Conclusions: Study results highlight the importance of the biopsychosocial model to enhance understanding of the needs of this complex population, and to design multi-dimensional approaches for providing more effective interventions to improve outcomes.
KW - Implementation science
KW - Models—biopsychosocial
KW - Patient-reported outcome measures
KW - Sickle cell disease
UR - http://www.scopus.com/inward/record.url?scp=85128727967&partnerID=8YFLogxK
U2 - 10.1007/s11136-022-03132-z
DO - 10.1007/s11136-022-03132-z
M3 - Article
C2 - 35445915
AN - SCOPUS:85128727967
SN - 0962-9343
VL - 31
SP - 2681
EP - 2694
JO - Quality of Life Research
JF - Quality of Life Research
IS - 9
ER -